Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of omalizumab alpha for moderate-to-severe allergic asthma
ChiCTR2400086969Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Peking University Third Hospital. Primary endpoint: Change in Asthma Control Test score from baseline at 24 weeks. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on ChiCTR2400086969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086969.